Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-06-20 4:01 pm Purchase | 13G | Rapport Therapeutics Inc. RAPP | Cormorant Asset Management LP | 2,940,283 8.04% | 2,940,283![]() (New Position) | View |
2024-05-13 4:00 pm Purchase | 13G | CytomX Therapeutics Inc. CTMX | Cormorant Asset Management LP | 5,750,000 7.38% | 5,750,000![]() (New Position) | View |
2024-04-29 4:02 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | Cormorant Asset Management LP | 2,500,000 5.15% | 2,500,000![]() (New Position) | View |
2024-04-15 6:10 pm Sale | 13G | Immuneering Corp IMRX | Cormorant Asset Management LP | 1,700,000 5.81% | -2,504,364![]() (-59.57%) | View |
2024-03-21 4:02 pm Purchase | 13G | Ventyx Biosciences Inc. VTYX | Cormorant Asset Management LP | 3,670,000 5.21% | 3,670,000![]() (New Position) | View |
2024-03-18 4:11 pm Purchase | 13G | Corbus Pharmaceuticals Holdings Inc. CRBP | Cormorant Asset Management LP | 2,025,000 19.3% | 2,025,000![]() (New Position) | View |
2024-02-14 3:08 pm Purchase | 13G | Neurogene Inc. NGNE | Cormorant Asset Management LP | 746,180 5.82% | 746,180![]() (New Position) | View |
2024-02-14 3:08 pm Sale | 13G | Aerovate Therapeutics Inc. AVTE | Cormorant Asset Management LP | 1,211,696 4.38% | -745,436![]() (-38.09%) | View |
2024-02-14 3:08 pm Purchase | 13G | Olema Pharmaceuticals Inc. OLMA | Cormorant Asset Management LP | 2,456,800 4.49% | 374,800![]() (+18.00%) | View |
2024-02-14 3:07 pm Sale | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Cormorant Asset Management LP | 2,550,000 4.39% | -300,000![]() (-10.53%) | View |
2024-02-14 3:07 pm Purchase | 13G | MARINUS PHARMACEUTICALS INC. MRNS | Cormorant Asset Management LP | 3,250,000 5.96% | 450,000![]() (+16.07%) | View |
2024-02-14 3:05 pm Purchase | 13G | Praxis Precision Medicines Inc. PRAX | Cormorant Asset Management LP | 633,345 7.39% | 633,345![]() (New Position) | View |
2024-02-14 3:04 pm Purchase | 13G | Tarsus Pharmaceuticals Inc. TARS | Cormorant Asset Management LP | 2,221,422 6.71% | 485,000![]() (+27.93%) | View |
2024-02-14 3:04 pm Purchase | 13G | LONGBOARD PHARMACEUTICALS INC LBPH | Cormorant Asset Management LP | 2,141,506 9.99% | 339,559![]() (+18.84%) | View |
2024-02-14 3:03 pm Sale | 13G | Korro Bio Inc. KRRO | Cormorant Asset Management LP | 529,170 6.61% | -150,000![]() (-22.09%) | View |
2024-02-14 3:03 pm Purchase | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 11,231,000 17.78% | 11,231,000![]() (New Position) | View |
2024-02-14 3:02 pm Sale | 13G | Monte Rosa Therapeutics Inc. GLUE | Cormorant Asset Management LP | 0 0% | -2,893,717![]() (Position Closed) | View |
2024-02-14 3:02 pm Sale | 13G | Elevation Oncology Inc. ELEV | Cormorant Asset Management LP | 0 0% | -1,952,032![]() (Position Closed) | View |
2024-02-14 3:01 pm Unchanged | 13G | Eledon Pharmaceuticals Inc. ELDN | Cormorant Asset Management LP | 0 0% | 0 (Unchanged) | View |
2024-02-14 3:01 pm Sale | 13G | Design Therapeutics Inc. DSGN | Cormorant Asset Management LP | 0 0% | -5,150,000![]() (Position Closed) | View |